Recent Company News

• 04:18 AM ET Apr 10, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (85 total)

• 04:44 AM ET Apr 07, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (90 total)

• 01:03 AM ET Apr 03, 2026
  

  AMF grants 26% holder Beech Tree exemption from requirement to make public tender offer for all Ipsen shares (€167.50, 0.00)

• 09:04 AM ET Mar 26, 2026
  

  Rhythm Pharmaceuticals receives positive CHMP Opinion for IMCIVREE for the treatment of obesity and control of hunger ($84.62, 0.00)

• 06:38 PM ET Mar 19, 2026
  

  FDA approves Rhythm Pharmaceuticals' IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity ($90.31, 0.00)

• 02:01 AM ET Mar 18, 2026
  

  Ipsen to showcase transformative potential of early immuno-oncology pipeline at AACR (€157.70, 0.00)

• 04:15 PM ET Mar 16, 2026
  

  Post-close news (and conference call)

• 04:04 PM ET Mar 16, 2026
  

  Rhythm Pharmaceuticals announces topline results from Phase 3 EMANATE trial; four substudies did not meet primary endpoints ($90.51, 0.00)

• 12:06 PM ET Mar 16, 2026
  

  PhotoCure announces two "trial in progress" presentations at the 2026 EAU Congress

• 10:43 AM ET Mar 09, 2026
  

  Jones comments on Oric Pharmaceuticals weakness and safety read-across from Ipsen drug ($11.98, -1.73)